Overview

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.
Phase:
Phase 2
Details
Lead Sponsor:
Foamix Ltd.
Vyne Therapeutics Inc.
Treatments:
Anti-Bacterial Agents
Cetuximab
Doxycycline